Fundraising FoxForesite Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalLongitude CapitalPalm Drive CapitalRA CapitalTCG CrossoverACORN BIOVENTURES+3 more
Foresight Diagnostics develops ultra-sensitive molecular diagnostic tests that combine genomics and bioinformatics to detect minimal residual disease and circulating tumor DNA across multiple cancer types.
BiotechDigital HealthHealthtechBoulder, US
Ash Alizadeh(Founder)David Kurtz(Founder)Jake Chabon(Founder)Maximilian Diehn(Founder)
Co-investorsAgent CapitalBoulder VenturesCivilization Ventures Management, LlcCU Healthcare Innovation FundPear VC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.